tetano
Editor, Senior Moderator
Pediatr Int. 2015 Apr 10. doi: 10.1111/ped.12658. [Epub ahead of print]
[h=1]Clinical findings in 10 children of H275Y influenza A(H1N1)pdm09 virus infection.[/h] Kakuya F[SUP]1[/SUP], Kinebuchi T, Fujiyasu H, Tanaka R, Okubo H, Kano H.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Little is known about the clinical effectiveness of neuraminidase inhibitors against H275Y influenza A(H1N1)pdm09 virus. A cluster of H275Y influenza A(H1N1)pdm09 virus with cross-resistance to oseltamivir and peramivir was detected among untreated community patients in Hokkaido, Japan, during the 2013-2014 influenza season.
[h=4]METHODS:[/h] This was a retrospective observational study. Specimens from nasopharyngeal swabs of patients were subjected to rapid testing and single nucleotide polymorphism identification by real-time polymerase chain reaction. We collected clinical data from the H275Y group and a 275H wild-type comparison group. All children were given one of four neuraminidase inhibitors.
[h=4]RESULTS:[/h] Twenty-eight children infected with influenza A(H1N1)pdm09 virus were analyzed. Ten viruses possessed the H275Y substitution, while the other 18 possessed wild-type 275H. Mean fever duration after treatment and after onset was 25.3 (95% confidence interval 14.1-36.5) h and 48.9 (34.4-63.3) h in the H275Y group, and 26.1 (18.7-33.6) h and 46.3 (35.7-56.8) h in the 275H group. In the H275Y group, three patients were treated with oseltamivir, one with peramivir, five with zanamivir, and one with laninamivir. All of them showed mild symptoms and received only outpatient care. Fever duration was 7.5-21.0 and 18.0-66.0 h after treatment and after onset in the patients treated with oseltamivir and peramivir, and 20.5-42.0 and 42.0-88.0 h in those treated with zanamivir and laninamivir.
[h=4]CONCLUSION:[/h] The fever of the H275Y group children treated with oseltamivir and peramivir resolved rapidly during the 2013-2014 influenza season.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] H275Y substitution; antiviral resistance; clinical effectiveness; influenza A(H1N1)pdm09; neuraminidase inhibitors
PMID: 25865177 [PubMed - as supplied by publisher]
[h=1]Clinical findings in 10 children of H275Y influenza A(H1N1)pdm09 virus infection.[/h] Kakuya F[SUP]1[/SUP], Kinebuchi T, Fujiyasu H, Tanaka R, Okubo H, Kano H.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Little is known about the clinical effectiveness of neuraminidase inhibitors against H275Y influenza A(H1N1)pdm09 virus. A cluster of H275Y influenza A(H1N1)pdm09 virus with cross-resistance to oseltamivir and peramivir was detected among untreated community patients in Hokkaido, Japan, during the 2013-2014 influenza season.
[h=4]METHODS:[/h] This was a retrospective observational study. Specimens from nasopharyngeal swabs of patients were subjected to rapid testing and single nucleotide polymorphism identification by real-time polymerase chain reaction. We collected clinical data from the H275Y group and a 275H wild-type comparison group. All children were given one of four neuraminidase inhibitors.
[h=4]RESULTS:[/h] Twenty-eight children infected with influenza A(H1N1)pdm09 virus were analyzed. Ten viruses possessed the H275Y substitution, while the other 18 possessed wild-type 275H. Mean fever duration after treatment and after onset was 25.3 (95% confidence interval 14.1-36.5) h and 48.9 (34.4-63.3) h in the H275Y group, and 26.1 (18.7-33.6) h and 46.3 (35.7-56.8) h in the 275H group. In the H275Y group, three patients were treated with oseltamivir, one with peramivir, five with zanamivir, and one with laninamivir. All of them showed mild symptoms and received only outpatient care. Fever duration was 7.5-21.0 and 18.0-66.0 h after treatment and after onset in the patients treated with oseltamivir and peramivir, and 20.5-42.0 and 42.0-88.0 h in those treated with zanamivir and laninamivir.
[h=4]CONCLUSION:[/h] The fever of the H275Y group children treated with oseltamivir and peramivir resolved rapidly during the 2013-2014 influenza season.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] H275Y substitution; antiviral resistance; clinical effectiveness; influenza A(H1N1)pdm09; neuraminidase inhibitors
PMID: 25865177 [PubMed - as supplied by publisher]